Suven Life Sciences Overview

  • Year Founded
  • 1989

Year Founded

  • Status
  • Public

  • Employees
  • 181

Employees

  • Stock Symbol
  • 530239

Stock Symbol

  • Share Price
  • $2.89
  • (As of Friday Closing)

Suven Life Sciences General Information

Description

Suven Life Sciences Ltd is an India-based clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India, the USA, Europe and the rest of the world. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.

Contact Information

Website
www.suven.com
Formerly Known As
Suven Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 6th Floor, SDE Serene Chambers
  • Avenue-7, Road Number 5, Banjara Hills
  • Hyderabad, Telangana 500034
  • India
+91 040
Primary Industry
Pharmaceuticals
Stock Exchange
BOM
Corporate Office
  • 6th Floor, SDE Serene Chambers
  • Avenue-7, Road Number 5, Banjara Hills
  • Hyderabad, Telangana 500034
  • India
+91 040

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Suven Life Sciences Stock Performance

As of 20-Nov-2026, Suven Life Sciences’s stock price is $2.89. Its current market cap is $815M with 283M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.89 $2.95 $1.33 - $4.24 $815M 283M 43.4K -$0.08

Suven Life Sciences Financials Summary

As of 30-Sep-2026, Suven Life Sciences has a trailing 12-month revenue of $981K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 923,442 342,366 268,894 237,217
Revenue 981 805 787 1,412
EBITDA (18,501) (31,101) (18,988) (13,993)
Net Income (19,415) (31,273) (19,010) (12,693)
Total Assets 52,724 66,158 15,804 34,164
Total Debt 1,668 1,769 0 85
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Suven Life Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Suven Life Sciences‘s full profile, request access.

Request a free trial

Suven Life Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Suven Life Sciences Ltd is an India-based clinical-stage biopharmaceutical company focused on the acquisition, developme
Pharmaceuticals
Hyderabad, India
181 As of 2026

Ahmedabad, India
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Suven Life Sciences Competitors (17)

One of Suven Life Sciences’s 17 competitors is Zydus Lifesciences, a Corporation company based in Ahmedabad, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zydus Lifesciences Corporation Ahmedabad, India
Glenmark Pharmaceuticals Corporation Mumbai, India
Sun Pharmaceutical Industries Corporation Mumbai, India
Jubilant Pharmova Corporation Noida, India
Aurobindo Pharma Corporation Hyderabad, India
You’re viewing 5 of 17 competitors. Get the full list »

Suven Life Sciences Patents

Suven Life Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026146402-A1 Pyrazolo and triazolopyridine derivatives as muscarinic m4 receptor positive allosteric modulators (m4 pams) Pending 30-Dec-2024
WO-2026047494-A1 2-amino-pyrimidine derivatives as muscarinic m4 receptor positive allosteric modulators (m4 pams) Pending 26-Aug-2024
AU-2024409574-A1 Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) Pending 22-Dec-2023
EP-4828664-A1 Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) Pending 22-Dec-2023
WO-2025134078-A1 Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) Inactive 22-Dec-2023 A61P25/16
To view Suven Life Sciences’s complete patent history, request access »

Suven Life Sciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Suven Life Sciences ESG

Risk Overview

Risk Rating

Updated October, 31, 2023

37.45 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 16,216

Rank

Percentile

Pharmaceuticals

Industry

of 921

Rank

Percentile

Pharmaceuticals

Subindustry

of 452

Rank

Percentile

To view Suven Life Sciences’s complete esg history, request access »

Suven Life Sciences FAQs

  • When was Suven Life Sciences founded?

    Suven Life Sciences was founded in 1989.

  • Where is Suven Life Sciences headquartered?

    Suven Life Sciences is headquartered in Hyderabad, India.

  • What is the size of Suven Life Sciences?

    Suven Life Sciences has 181 total employees.

  • What industry is Suven Life Sciences in?

    Suven Life Sciences’s primary industry is Pharmaceuticals.

  • Is Suven Life Sciences a private or public company?

    Suven Life Sciences is a Public company.

  • What is Suven Life Sciences’s stock symbol?

    The ticker symbol for Suven Life Sciences is 530239.

  • What is the current stock price of Suven Life Sciences?

    As of 20-Nov-2026 the stock price of Suven Life Sciences is $2.89.

  • What is the current market cap of Suven Life Sciences?

    The current market capitalization of Suven Life Sciences is $815M.

  • What is Suven Life Sciences’s current revenue?

    The trailing twelve month revenue for Suven Life Sciences is $981K.

  • Who are Suven Life Sciences’s competitors?

    Zydus Lifesciences, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries, Jubilant Pharmova, and Aurobindo Pharma are some of the 17 competitors of Suven Life Sciences.

  • What is Suven Life Sciences’s annual earnings per share (EPS)?

    Suven Life Sciences’s EPS for 12 months was -$0.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process